Drug discovery articles from across Nature Portfolio

A randomized phase 2a clinical trial of an AI-discovered drug and target combination for idiopathic pulmonary fibrosis shows safety and signs of efficacy, marking a concrete step forward in bringing AI-enabled drug discovery into the clinic.

Salicylic acid nitroalkene (SANA) is a derivative of the aspirin precursor, salicylate. We discovered that SANA effectively reduces body weight in a mouse model of diet-induced obesity by stimulating creatine-dependent thermogenesis. In preliminary human trials, SANA was found to be safe, well-tolerated and demonstrated promising results in promoting weight loss.

A randomized phase 2a clinical trial of an AI-discovered drug and target combination for idiopathic pulmonary fibrosis shows safety and signs of efficacy, marking a concrete step forward in bringing AI-enabled drug discovery into the clinic.

Salicylic acid nitroalkene (SANA) is a derivative of the aspirin precursor, salicylate. We discovered that SANA effectively reduces body weight in a mouse model of diet-induced obesity by stimulating creatine-dependent thermogenesis. In preliminary human trials, SANA was found to be safe, well-tolerated and demonstrated promising results in promoting weight loss.

Drugs currently being tested target complications associated with obesity such as heart disease, fatty liver disease and type 2 diabetes.

Study highlights potential for sustainable synthesis of paracetamol.